Pfizer sees strong response to pediatric pneumonia vaccine in phase 2 trial
FROM THE WIRE · SEEKINGALPHA.COM
[Flu Shot] FatCamera/iStock via Getty Images * Data from a phase 2 trial of Pfizer's (PFE [https://seekingalpha.com/symbol/PFE]) pediatric 25-valent pneumococcal conjugate vaccine PF-07872412 (25vPnC) showed that a four-dose series of the candidate provoked a robust immune…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishPositive clinical trial data for a candidate vaccine from a large pharma company.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01The 25vPnC candidate produced a robust immune response against all 25 serotypes.
- 02Safety and tolerability were similar to four doses of Prevnar 20.
- 03The study enrolled about 400 full-term infants.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets